Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe

LAVAL, Quebec, Oct. 3, 2017 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"), today announced the introduction of Biotrue^® ONEday for Astigmatism daily disposable contact lenses in 20 countries in Europe. This latest contact lens advancement provides the convenience of a daily disposable with the innovation of an evolved peri-ballast design for stability and a unique dehydration barrier proven to help the lens maintain 98% of its moisture for up to 16 hours.¹

"The Biotrue^® ONEday for Astigmatism contact lenses were developed by our in-house team of scientists and contact lens designers to meet the needs of today's astigmatic patients," said Joseph C. Papa, chairman and CEO, Valeant. "The full spectrum of Biotrue® ONEday products, which also includes Biotrue^® ONEday Single Vision and Biotrue^® ONEday for Presbyopia contact lenses, is now an option for patients across many countries in Europe."

As part of the development process for the lens, Bausch + Lomb evaluated various ballasting mechanisms and assessed dynamics of blink patterns across a wide range of patients using high speed videography. To achieve the combination that performed the best in the high-water content material of Biotrue^® ONEday contact lenses, engineers created an evolved lens design incorporating advanced optics to help reduce halos and glare, even in low-light conditions.²

Biotrue® ONEday for Astigmatism is now available in Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, and the United Kingdom. In total, 21 countries, including the United States, currently offer all three modalities of Biotrue® ONEday contact lenses, which are manufactured and distributed globally from the company's facility in Waterford, Ireland.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufacturers and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com. 

Forward-looking Statements
This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates, "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

SOURCE Valeant Pharmaceuticals International, Inc.

Related Links

http://www.valeant.com